10x Genomics Long Term Debt

The latest long-term debt for TXG is $70M as of March 2026. That compares with $71M in the prior-year period — down 0.8% year over year. Investors often review this figure alongside 10x Genomics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TXG's long-term debt moved from $71M to $70M — a 0.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 10x Genomics's operating scale or balance-sheet position.

A long-term debt figure of $70M for TXG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TXG's long-term debt ($70M), review year-over-year change from $71M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack 10x Genomics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.